Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4 ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Kisqali ® (ribociclib) is a selective cyclin-dependent kinase inhibitor ... Tell your health care provider or get medical help right away if you get severe rash or rash that keeps getting worse; ...

But itchy and flaky red rashes appeared across his body a few years ago, making it excruciating to move, he said. The pain forced Mr. Brann, a 62-year-old former shoe manufacturer, to retire early.

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...